Myelodysplastic syndromes - PubMed (original) (raw)

Review

. 2008 May 15;111(10):4841-51.

doi: 10.1182/blood-2007-08-078139.

Affiliations

• PMID: 18467609
• DOI: 10.1182/blood-2007-08-078139

Free article

Review

Myelodysplastic syndromes

Stephen D Nimer. Blood. 2008.

Free article

Abstract

There has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell. Our understanding of the pathogenesis of the myelodysplastic syndromes (MDSs) has lagged behind, at least in part, because they represent a more heterogeneous group of disorders. The significant immunologic abnormalities described in this disease, coupled with the admixture of MDS stem or progenitor cells within the myriad types of dysplastic and normal cells in the bone marrow and peripheral blood, have made it difficult to molecularly characterize and model MDS. The recent availability of several, effective (ie, FDA-approved) therapies for MDS and newly described mouse models that mimic aspects of the human disease provide an opportune moment to try to leverage this new knowledge into a better understanding of and better therapies for MDS.

PubMed Disclaimer

Similar articles

• Etiopathogeny, prognosis and therapy of myelodysplastic syndromes.
  Sanz GF, Sanz MA, Vallespi T. Sanz GF, et al. Hematol Cell Ther. 1997 Dec;39(6):277-94. doi: 10.1007/s00282-997-0277-z. Hematol Cell Ther. 1997. PMID: 9497887 Review.
• [Myelodysplastic syndromes: preleukemic syndromes].
  Tassin F, Hermanne JP, Schaaf-Lafontaine N, Herens C, Thiry A, Paulus JM, Boniver J, Fillet G. Tassin F, et al. Rev Med Liege. 1998 Jun;53(6):357-62. Rev Med Liege. 1998. PMID: 9713217 Review. French.
• [Myelodysplastic syndrome: a review].
  Creutzig U, Hoelzer D. Creutzig U, et al. Klin Padiatr. 1987 May-Jun;199(3):169-72. doi: 10.1055/s-2008-1026784. Klin Padiatr. 1987. PMID: 3626418 German.
• Refractory anemia and the myelodysplastic syndromes.
  Lawrence LW. Lawrence LW. Clin Lab Sci. 2004 Summer;17(3):178-86. Clin Lab Sci. 2004. PMID: 15314893 Review.
• The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
  Das M, Chatterjee S, Basak P, Das P, Pereira JA, Dutta RK, Chaklader M, Chaudhuri S, Law S. Das M, et al. J Stem Cells. 2010;5(2):49-64. J Stem Cells. 2010. PMID: 22049615

Cited by

• Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
  Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT. Rhyasen GW, et al. Cancer Cell. 2013 Jul 8;24(1):90-104. doi: 10.1016/j.ccr.2013.05.006. Cancer Cell. 2013. PMID: 23845443 Free PMC article.
• Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
  Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, Tian X, Kwak M, Wilhelm F, Yong AS, Maric I, Maniar M, Scheinberg P, Groopman J, Young NS, Sloand EM. Olnes MJ, et al. Leuk Res. 2012 Aug;36(8):982-9. doi: 10.1016/j.leukres.2012.04.002. Epub 2012 Apr 21. Leuk Res. 2012. PMID: 22524974 Free PMC article. Clinical Trial.
• Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
  Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT. Fang J, et al. Blood. 2012 Jul 26;120(4):858-67. doi: 10.1182/blood-2012-02-407999. Epub 2012 Jun 8. Blood. 2012. PMID: 22685174 Free PMC article.
• What's all the fuss about? facts and figures about bone marrow failure and conditions.
  Mukherjee S, Sekeres MA. Mukherjee S, et al. Curr Hematol Malig Rep. 2012 Dec;7(4):300-9. doi: 10.1007/s11899-012-0134-1. Curr Hematol Malig Rep. 2012. PMID: 22936422 Review.
• Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.
  Lee BH, Kang KW, Jeon MJ, Yu ES, Kim DS, Choi H, Lee SR, Sung HJ, Kim BS, Choi CW, Park Y. Lee BH, et al. Sci Rep. 2020 Jan 8;10(1):39. doi: 10.1038/s41598-019-56642-1. Sci Rep. 2020. PMID: 31913293 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal